RxDoctor Payments Data

Jennifer Taylor, MD

Critical Care Medicine · Aurora, CONPI 1831501196

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Abiomed at 50.8% of the total. 2025 is the largest year on record at $1,046, 4.9 times the $215 reported in 2022.

$1,846in general payments, 2019–2025

Across 27 payments — averaging $68.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$937
  • Inari Medical, Inc.$389
  • Medtronic$184
  • Servier Pharmaceuticals LLC$98
  • GSK$92
  • BD$48
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$1,846100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,846 in reported general payments places this provider in the 70th percentile of 141 critical care medicine providers in Colorado.

See all critical care medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$110,636
Medicare patients
330
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$185,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$43,629
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,049
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,724
Spiriva RespimatTiotropium Bromide17$9,671
SymbicortBudesonide/Formoterol Fumarate19$5,499
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$1,978
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$1,782
Albuterol Sulfate HfaAlbuterol Sulfate32$856
Fluticasone Propionate15$387
Azithromycin30$167
Omeprazole15$157
Prednisone22$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$92$55,35375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 141 critical care medicine providers in Colorado.

Other critical care medicine in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →